All In Biotech

Drug Trial Radar · NCT06740214

Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty

Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty: a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

177

Planned (sponsor's estimate)

Start

Sep 4, 2025

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Total knee arthroplasty is a commonly performed orthopaedic surgery for the treatment of end-stage osteoarthritis when conservative management becomes ineffective. TKA is associated with significant acute postoperative pain and many patients experience severe postoperative pain despite the use of multimodal analgesia. Poor acute postoperative pain control impacts rehabilitation, prolongs recovery and increases opioid consumption and chronic post-surgical pain. Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can extend the duration of analgesia. The adductor canal block (ACB) has been shown to reduce pain intensity and opioid consumption after total knee arthroplasty. The use of liposomal bupivacaine in the adductor canal block has recently been FDA-approved. However, the results of its efficacy from existing clinical trials have been mixed. In addition, the doses in the clinical trials have been different, and the optimal dose for perineural application of liposomal bupivacaine is unclear, including for the adductor canal block. In this project, the investigators propose to conduct a randomized controlled trial to investigate the effect of different doses of liposomal bupivacaine in the adductor canal block on acute postoperative pain intensity and opioid consumption after robotic assisted total knee arthroplasty. The investigators will also assess secondary outcomes including knee functional scores, chronic pain and quality of recovery.

Conditions

  • Pain, Postoperative
  • Analgesic Effect
  • Total Knee Arthroplasty
  • Liposomal Bupivacaine
  • Dose Response Relationship, Drug

Interventions

  • 0.5% standard bupivacaine onlyDrug

    20ml 0.5% standard bupivacaine only

  • 1.33% liposomal bupivacaine with 0.5% standard bupivacaineDrug

    10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine

  • 1.33% liposomal bupivacaine onlyDrug

    20ml 1.33% liposomal bupivacaine (266mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Weighted area under curve (AUC) pain scoreTime frame: The first 48 hours after surgery when the patient is at rest

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Hong Kong

    Hong Kong, Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.